Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma

British Journal of Haematology

Volumn 137, Issue 5, 2007, Pages 429-435

  Richardson, Paul G ^a   Sonneveld, Pieter ^b   Schuster, Michael W ^c   Irwin, David ^d   Stadtmauer, Edward A ^e   Facon, Thierry ^f   Harousseau, Jean Luc ^g   Ben Yehuda, Dina ^h   Lonial, Sagar ⁱ   San Miguel, Jesús F ^j   Cavenagh, Jamie D ^k   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d Alta Bates Comprehensive Cancer Center   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f LILLE UNIVERSITY HOSPITAL   (France)

^g HÔTEL DIEU   (France)

^h HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

ⁱ EMORY UNIVERSITY   (United States)

^j HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^k ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

more..

Author keywords

Bortezomib; Elderly; High risk; ISS staging; Multiple myeloma

Indexed keywords

BORTEZOMIB;

ADULT; AGED; ANEMIA; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FATIGUE; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CHI-SQUARE DISTRIBUTION; DEXAMETHASONE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FATIGUE; GLUCOCORTICOIDS; HUMANS; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; PYRAZINES; RISK; THROMBOCYTOPENIA;

EID: 34247846013     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06585.x     Document Type: Article

References (19)

1. Attal, M., Harousseau, J-L., Stoppa, A-M., Sotto, J-J., Fuzibet, J-G., Rossi, J-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., Payen, C. Bataille, R. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New England Journal of Medicine, 335, 91 97.
2. Bladé, J., Munoz, M., Fontanillas, M., San Miguel, J., Alcala, A., Maldonado, J., Besses, C., Moro, M.J., Gardia-Conde, J., Rozman, C., Montserrat, E. Estapé, J. (1996) Treatment of multiple myeloma in elderly people: long-term results in 178 patients. Age and Ageing, 25, 357 361.
3. Bladé, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115 1123.
4. Durie, B.G.M., Stock-Novack, D., Salmon, S.E., Finley, P., Beckord, J., Crowley, J. Coltman, C.A. (1990) Prognostic value of pretreatment serum β2 microglobulin in myeloma: a Southwest Oncology Group study. Blood, 75, 823 830.
5. Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Genevieve, F., Zandecki, M., Lai, J-L., Leleu, X., Jouet, J-P., Bauters, F., Harousseau, J-L., Bataille, R. Mary, J-Y. (2001) Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood, 97, 1566 1571.
6. Greipp, P.R., Lust, J.A., O'Fallon, M., Katzmann, J.A., Witzig, T.E. Kyle, R.A. (1993) Plasma cell labeling index and β2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood, 81, 3382 3387.
7. Greipp, P.R., San Miguel, J., Durie, B.G.M., Crowley, J.J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J.A., Avet-Loiseau, H., Kyle, R.A., Lahuerta, J.J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I. Westin, J. (2005) International Staging System for myeloma. Journal of Clinical Oncology, 23, 3412 3420.
8. Jacobson, J.L., Hussein, M.A., Barlogie, B., Durie, B.G. Crowley, J.J. (2003) A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. British Journal of Haematology, 122, 441 450.
9. Jagannath, S., Barlogie, B., Berenson, J., Sigel, D., Irwin, D., Richardson, P.G., Niesvizky, R., Alexanian, R., Limentani, S.A., Alsina, M., Adams, J., Kauffman, M., Esseltine, D-L., Schenkein, D.P. Anderson, K.C. (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal of Haematology, 127, 165 172.
10. Kane, R.C., Farrell, A.T., Sridhara, R. Pazdur, R. (2006) United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clinical Cancer Research, 12, 2955 2960.
11. Kumar, S.K., Therneau, T.M., Gertz, M.A., Lacy, M.Q., Dispenzieri, A., Rajkumar, S.V., Fonseca, R., Witzig, T.E., Lust, J.A., Larson, D.R., Kyle, R.A. Greipp, P.R. (2004) Clinical course of patients with relapsed multiple myeloma. Mayo Clinic Proceedings, 79, 867 874.
12. Kyle, R.A., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q., Dispenzieri, A., Fonseca, R., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.E., Therneau, T.M. Greipp, P.R. (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 78, 21 33.
13. Lonial, S., Waller, E.K., Richardson, P.G., Jagannath, S., Orlowski, R.Z., Giver, C.R., Jaye, D.L., Francis, D., Giusti, S., Torre, C., Barlogie, B., Berenson, J.R., Singhal, S., Schenkein, D.P., Esseltine, D-L.W., Anderson, J., Ziao, H., Heffner, L.T. Anderson, K.C. (2005) Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood, 106, 3777 3784.
14. Mileshkin, L. Prince, H.M. (2005) The adverse prognostic impact of advanced age in multiple myeloma. Leukemia & Lymphoma, 46, 951 966.
15. Mileshkin, L., Biagi, J.J., Mitchell, P., Underhill, C., Grigg, A., Bell, R., McKendrick, J., Briggs, P., Seymour, J.F., Lillie, K., Smith, J.G., Zeldis, J.B. Prince, H.M. (2003) Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood, 102, 69 77.
16. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D-L., Kauffman, M., Adams, J., Schenkein, D. Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609 2617.
17. Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J-L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San Miguel, J.F., Bladé, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. Anderson, K.C. (2005a) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 2487 2498.
18. Richardson, P., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San Miguel, J., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W., Boral, A., Schenkein, D. Anderson, K. (2005b) Bortezomib continues to demonstrate superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trial. Blood, 106, 715a (Abstract no. 2547).
19. Richardson, P.G.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Hideshima, T., Ziao, H., Esseltine, D., Schenkein, D. Anderson, K.C. (2005c) Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood, 106, 2977 2981.